Design, synthesis, and evaluations of substituted 3-[(3- or 4- carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

Journal of Medicinal Chemistry

Volumn 42, Issue 25, 1999, Pages 5120-5130

  Sun, Li ^a   Tran, Ngoc ^a   Liang, Congxin ^a   Tang, Flora ^a   Rice, Audie ^a   Schreck, Randall ^a   Waltz, Kara ^a   Shawver, Laura K ^a   McMahon, Gerald ^a   Tang, Cho ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 INDOLINONE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRROLE DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL GROWTH; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTORS; HUMANS; INDOLES; LYMPHOKINES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 19244370071     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9904295     Document Type: Article

References (15)

1. Kolibaba, K. S.; Druker, B. J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1997, 1333, F217-F248.
2. Cantley, L. C.; Auger, K. R.; Carpenter, C.; Duckworth, B.; Graziani, A.; Kapeller, R.; Soltoff, S. Oncogenes and signal transaction. Cell 1991, 64, 281-302.
3. Merenmies, J.; Parada, L. F.; Henkemeyer, M. Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ. 1997, 8, 3-310.
4. Shawver, L. K.; Lipson, K. E.; Fong, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today 1997, 2 (2), 50-63.
5. Plowman, G. D.; Ullrich, A.; Shawver, L. K. Receptor tyrosine kinases as targets for drug intervention. DN&P 1994, 7 (6), 334-339.
6. Sun, L.; Tran, N.; Tang, T.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity towards particular receptor tyrosine kinases. J. Med. Chem. 1998, 41 (14), 2588-2603.
7. Mohammadi, M.; McMahon, G., Sun, L.; Tang, P. C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
8. Fong, A. T. T.; Shawver, L. K.; Sun, L.; Tang, C.; App. H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X. Y.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59, 99-106.
9. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17 (20), 5896-5904.
10. Quallich, G. J.; Morrissey, P. M. A general oxindole synthesis. Synthesis 1993, 1, 51-53.
11. Ogawa, H.; Tamada, S.; Fujioka, T.; Teramoto, S.; Kondo, K.; Yamashita, S.; Yabuuchi, Y.; Tominaga, M.; Nakagawa, K. Studies on Positive Inotropic Agents. V. Synthesis of 1-Heteroaroylpiperazine Derivatives. Chem. Pharm. Bull. 1988, 36, 2253-2258.
12. Tang, C.; Nematalla, A.; Sun, L.; Andrews, S.; Garst, M. Improved synthesis of potent tyrosine kinase inhibitor. Manuscript in preparation.
13. Woodward, R. B.; Ayer, W. A.; Beaton, J. M.; Bickelhaupt, F.; Bonnett, R.; Buchschacher, P.; Closs, G. L.; Dutler, H.; Hannah, J.; Hauck, F. P.; Ito, S.; Langemann, A.; Goff, E. L.; Leimgruber, W.; Lwowski, W.; Sauer, J.; Valenta, Z.; Volz, H. Tetrahedron 1990, 46 (22), 7599-7659.
14. Strawn, L. M.; McMahon, G.; App, H.; Schreck, R.; Kuchler, W. R.; Longhi, M. P.; Hui, T. H.; Tang, C.; Levitzki, A.; Gazit, A.; Chen, I.; Keri, G.; Orfi, L.; Risau, W.; Flamme, I.; Ullrich, A.; Hirth, K. P.; Shawver, L. K. Flk-1/KDR as a target for tumor growth inhibition. Cancer Res. 1996, 56, 3540-3545.
15. Hanks, S.; Quinn, A. M. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Methods Enzymol. 1991, 200, 38-62.